Preparation of benzylic α,α-difluoronitriles, -tetrazoles, and -sulfonates via electrophilic fluorination

Journal of Organic Chemistry

Volumn 63, Issue 22, 1998, Pages 8052-8057

  Kotoris, Christopher C ^a   Chen, Mei Jin ^a   Taylor, Scott D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001090596     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo981163x     Document Type: Article

References (49)

1. Welch, J. T.; Eswarakrishnan, S. Fluorine in Bioorganic Chemistry; John Wiley and Sons: New York, 1991.
2. For some examples of a,a-difluorophosphonates as inhibitors of enzymes other than FTP's, see: Halazy, S.; Ehrhard, A.; Eggenspiller, A.; Berges-Gross, V.; Danzin, C. Tetrahedron 1996,51,177.
3. Blackburn, G. M.; Kent, D. E.; Kolkmann, F. J. Chem. Soc., Ferkln Trans, l 1984, 1119.
4. Hebel, D.; Kirk, K. L.; Kinjo, J.; Kovacs, T.; Lesiak, K.; Baizarini, J.; De Clercq, E.; Torrence, P. F. Bioorg. Med. Chem. Lett. 1991, l, 357.
5. (a) Burke, T. R.; Kole, H. K.; Roller, P. P. Biochem. Biophys. Res. Commun. 1994, 204, 129.
6. (b) Chen, L.; Wu, L.; Otaka, A.; Smyth, M. S.; Roller, P. R.; Burke, T. R.; den Hertog, J.; Zhang, Z.-Y. Biochem. Biophys. Res. Commun. 1995, 216, 976.
7. (a) Kole, K. H.; Smyth, M. S.; RUSS, P. L.; Burke, T. R. Biochem. J. 1995,311,1025.
8. (b) Taylor, S. D.; Kotoris, C. C.; Dinaut, A. N.; Wang, Q.; Ramachandran, C.; Huang, H. Bioorg. Med. Chem., in press.
9. Wang, Q.; Huang, Z.; Ramachandran, C.; Dinaut, A. N.; Taylor, S. D. Bioorg. Med. Chem. Lett. 1998, 8, 345.
10. (a) Taylor, S. D.; Kotoris, C. C.; Dinaut, A. N.; Chen, M.-J. Tetrahedron 1998, 54,1691.
11. (b) Taylor, S. D.; Dinaut, A. N.; Thadani, A. T.; Huang, Z. Tetrahedron Lett. 1996, 37, 8089.
12. Stankovic, C. J.; Surendram, N.; Lunney, E. A.; Plummer, M. S.; Para, K. S.; Shahripour, A.; Fergus, J. H.; Marks, J. S.; Herrera, R.; Hubbell, S. E.; Humblet, C.; Saltiel, A. R.; Stewart, B. H.; Sawyer, T. K. Bioorg. Med. Chem. Lett. 1997, 7, 1909.
13. (a) Middleton, W. J.; Bingham, E. M. J. Org. Chem. 1980, 45, 2883.
14. (b) Bartmann, E.; Krause, J. J. Fluorine Chem. 1993, 61, 117.
15. Hagele, G.; Haas, A. J. Fluorine Chem. 1996, 76,15.
16. Yagupolskii, L. M.; Belinskaya, R. V. Zh. Obshch. Khim. 1958,28, 772.
17. (e) Bardin, V. V.; Furin, G. G.; Yakobson, G. G. Zh. Org. Khim. 1984,20, 567.
18. (f) Laurent, E.; Marquet, B.; Tardivel, R. Tetrahedron 1989, 45, 4431.
19. (a) Finnegan, W. G.; Henry, R. A.; Lofquist, R. J. Am. Chem. Soc. 1958,80,3908.
20. (b) Wittenberger, S. J.; Donner, B. G. J. Org. Chem. 1993, 58, 4139.
21. Thomas, E. W. Synthesis 1993, 767.
22. Duncia, J. V.; Pierce, M. E.; Santella, J. B. J. Org. Chem. 1991, 56, 2395.
23. For a review on electrophilic fluorination, see: Rozen, S. Chem. Rev. 1996, 96, 1717.
24. For some examples of electrophilic fluorination using NFSi, see: (a) McAtee, J. J.; Schinazi, R. F.; Liotta, D. C. J. Org. Chem. 1998, 63, 2161.
25. (b) Ender, D.; Potthoff, M.; Raabe, G.; Runsink, J. Angew. Chem., Int. Ed. Engl. 1997, 36, 2362.
26. Difierding, E.; Ofner, H. Synlett 1991, 187.
27. Difierding, E.; Duthaler, R. O.; Kreiger, A.; Ruegg, G. M.; Schmit, C. Synlett 1991, 395.
28. 8c However, we were unable to obtain any appreciable quantities of 20 in pure form using this procedure.
29. The tert-butyl group is commonly employed as a protecting group for tetrazoles and is removed using acid. For example, see: Tilley, J. W.; Danho, W.; Lovey, K.; Wagner, R.; Swistok, J.; Makofske, R.; Michaelewsky, J.; Triscari, J.; Nelson, D.; Weatherford, S. J. Med. Chem. 1991, 34, 1125.
30. For some examples of biologically active benzylic tetrazoles, see: Bleisch, T. J.; Ornstein, P. L.; Alien, N. K.; Wright, R. A.; Lodge, D.; Schoepp, D. D. Bioorg. Med. Chem. Lett. 1997, 7, 1161.
31. Kogan, T. P.; Dupre, B.; Keller, K. M.; Scott, I. L.; Bui, H.; Market, R. V.; Beck, P. J.; Vogtus, J. A.; Revelle, B. M.; Scott, D. J. Med. Chem. 1995, 38, 4976.
32. Al-Khamees, H. A.; Kandil, H. A.; El-Tahir, K. E. H.; Al-Attas, O. S.; Bayomi, S. M. Sei. Pharm. 1994, 62, 363.
33. Kees, K. L.; Smith, T. M.; McCaleb, M. L.; Prozialeck, D. H.; Cheeseman, R. S.; Christas, J. A.; Patt, W. C.; Steiner, K. E. J. Med. Chem. 1992,35, 944.
34. Ornstein, P. L.; Schoepp, D. D.; Arnold, M. B.; Augenstein, N. K.; Lodge, D.; Millar, J. P.; Chambers, J.; Campbell, J.; Paschal, J. W.; Zimmerman, D. M.; Leander, J. D. J. Med. Chem. 1992, 35, 3547.
35. Musser, J. H.; Kreft, A. F.; Bender, R. H. W.; Kubrak, D. M.; Grimes, D.; Carolson, R. P.; Hand, J. M.; Chang, J. J. Med. Chem. 1990, 33, 240.
36. Huang, F.-C.; Galemmo, R. A.; Johnson, W. H.; Poli, G. B.; Morrisette, M. M.; Mencel, J. J.; Warus, J. P.; Campbell, H. F.; NUSS, G. W.; Carnathan, G. W.; van Inwegen, R. G. J. Med. Chem. 1990,33,1194.
37. Gapinski, D. M.; Mallet, B. E.; Froelich, L. L.; Jackson, W. T. J. Med. Chem. 1990, 33, 2798. See also ref 13.
38. Liotta, A. S.; Kole, H. K.; Fales, H. M.; Roth, J.; Bernier, M. J. Biol. Chem. 1994,269, 22996.
39. Desmarais, S.; Jia, Z.; Ramachandran, R. Arch. Kochern. Biophys. 1998, 354, 225.
40. Sulfonates are completely ionized at physiological pH. Thus, any increase in inhibitor potency of a,a-difluorosulfonates compared to their nonfluorinated or sulfate counterparts would have to be a result of a direct interaction of the fluorines with residues in the enzyme active site, as. appears to be the case with the a-difluorinated phosphonates and PTP's.
41. For examples, see: (a) Selcer, K. W.; Hegde, P. V.; Li, P.-K. Cancer Res. 1997, 57, 702.
42. (b) Anderson, C.; Freeman, J.; Lucas, L. H.; Parley, M.; Dalhoumi, H.; Widlanski, T. S. Biochemistry 1997,36, 2586.
43. Howarth, N. M.; Purolit, A.; Reed, M. J.; Potter, B. V. L. Steroids 1997,62,346.
44. Li, P. K.; Pillai, R.; Dibbelt, L. Steroids 1995, 60, 299.
45. Ruechardt, C.; Grundmeier, M. Chem. Ber. 1975,108, 2448.
46. Mulder, R. J.; van Leusen, A. M.; Strating, J. Tetrahedron Lett. 1967, 3057.
47. Truce, W. E. Can. J. Chem. 1969, 47, 860.
48. King, J. F.; Durst, T. J. Am. Chem. Soc. 1965, 87, 5684.
49. 18a-d some of which are estrone sulfonates in which the labile S-O bond in the substrate is replaced by a méthylène unit.18d Conversion of these compounds to the α,α-difluorosulfonate derivatives may provide a means of increasing the potency of these compounds.